studies only included severe psoriasis patients and performed limited cardiometabolic testing. Furthermore, small sample sizes did not permit stratified analyses or adjustment for multiple potential confounders. FDG uptake in the blood vessel wall by PET/CT is associated with activated endothelial cells 15 and cellular infiltration in noncalcified, atherosclerotic plaques. 16 Prior studies demonstrate that FDG in the vessel wall is taken up by macrophages, which are CD68 + cells critical in atherogenesis. 17 Furthermore, recent investigations have demonstrated that FDG uptake directly associates with vascular inflammation and reliably detects changes in atherosclerotic plaques in at-risk populations, including individuals with rheumatoid arthritis and those infected with HIV. [18] [19] [20] Notably, vascular uptake of FDG is associated with future cardiovascular events and improves with lifestyle modification and statin therapy. 21, 22 These findings demonstrate that FDG PET/CT provides a reliable and reproducible measure to characterize the relationship between psoriasis severity and vascular inflammation.
There are differential gene expression signatures in psoriatic skin plaques 23 with associated changes in protein levels of these same genes in the blood associated with cardiovascular diseases. 24 Furthermore, accumulating evidence suggests that shared biological pathways between psoriasis and cardiometabolic diseases 25, 26 may provide a plausible link between psoriasis severity and vascular diseases. Moreover, large population-based studies demonstrate that body surface area affected by psoriasis directly correlates with cardiometabolic diseases. 27, 28 Thus, we hypothesized that psoriatic skin disease severity quantified by the psoriasis area severity index (PASI) score would be associated with vascular inflammation measured by FDG PET/CT. Neutrophils are the earliest cells present in psoriatic plaques, and recent data indicate that neutrophils may be one of the predominant cellular sources of proinflammatory cytokine interleukin (IL)-17 in psoriatic skin disease. 29 Studies also suggest that there may be an important role for peripheral blood neutrophils in psoriasis comorbidities, including coronary artery disease. 30 Therefore, proteins associated with neutrophils, such as myeloperoxidase (MPO), S100A8/A9, and neutrophil elastase-1 (NE-1), may further provide a link between psoriasis and cardiometabolic diseases. Therefore, our objective in this study was to characterize the relationship between directly measured psoriatic skin disease and vascular inflammation and to perform studies aimed at exploring the biological link between these 2 disease entities by characterizing neutrophil frequency, activation, and proteins in psoriasis.
Materials and Methods
Complete details of Materials and Methods, including participant selection, clinical assessments, imaging procedures and analyses, and translational studies, are available in the online-only Data Supplement.
Results

Study Population
Recruitment scheme ( Figure 1 ) and characteristics of the psoriasis (n=60) and the age-and sex-matched control (n=20) study populations are presented (Table 1) 
Psoriasis Severity Is Associated With Vascular Inflammation Independent of Cardiovascular Risk Factors
In unadjusted linear regression models, increasing PASI score was associated with an increase in vascular inflammation as measured by aortic TBR (β=0.41, P=0.001). This relationship remained significant after adjusting for age and sex (β=0.39, P=0.002) and FRS (β=0.39, P=0.001; Table 2 and Figure 2A and 2B).
Psoriasis Severity Predicts Vascular Inflammation Beyond FRS and High-Sensitivity C-Reactive Protein in Fully Adjusted Models
The contribution of PASI score in predicting vascular inflammation (aortic TBR) beyond FRS and high-sensitivity C-reactive protein was determined using likelihood ratio testing in nested models (Table 3) . PASI score added incremental value beyond FRS (χ 2 =8.66, P<0.01) and high-sensitivity C-reactive protein (χ 2 =6.48, P=0.01) when added to nested models, suggesting that psoriatic skin disease severity independently increases vascular inflammation.
Cytokines Associated With Innate Immune Activation and Cytokines That Modulate Neutrophil Biology Are Elevated in Psoriasis Plasma
Markers of increased innate immune activation, including IL-6 (mean psoriasis 1.58±0.37 versus controls 0.56±0.06 pg/ mL; P=0.044) and tumor necrosis factor-α (mean psoriasis 7.16±2.49 versus controls 1.53±0.09 pg/mL; P=0.002), were increased in psoriasis patients ( Figure 3 ). We then hypothesized that skin disease severity may be associated with vascular inflammation via neutrophils. Consistent with this, we observed increased levels of cytokines associated with neutrophil recruitment, differentiation, activation, and release 31 ; granulocyte macrophage colony-stimulating factor (GM-CSF; mean psoriasis 0.34±0.03 versus controls 0.23±0.04 pg/mL; P=0.049) and IL-17 (mean psoriasis 3.51±0.84 versus controls 1.83±0.51 pg/mL; P=0.05) were elevated in psoriasis plasma compared with that of controls ( Figure 3 ).
Neutrophil Frequencies, Activation, and Markers Are Elevated in Psoriasis
After observing that absolute neutrophil count Figure 4C ). Subsequent analysis 
Neutrophils Relate to Skin Disease and S100A8/ A9 Relates to Both Skin and Vascular Disease
We examined whether absolute neutrophil 32 counts related to psoriasis severity and found that absolute neutrophil count was related to PASI score (β=0.24; P=0.03). Finally, we tested whether these neutrophil markers were related to PASI score (Table 4 ) and vascular inflammation (Table 5) . Neither MPO (β=−0.06; P=0.82) nor NE-1 (β=−0.16; P=0.47) related to PASI score in fully adjusted models. However, S100A8/ A9 (β=0.53; P=0.02) showed a relationship with psoriasis severity beyond adjustment for FRS. Similarly, neither MPO (β=−0.20; P=0.32) nor NE-1 (β=0.08; P=0.49) related to vascular inflammation, but a relationship was observed between S100A8/A9 and vascular inflammation when adjusted for FRS (β=0.48; P=0.02; Table 5 and Figure 6 ). These findings suggest that this S100A8/A9 protein may serve as a mediator or by-product in one of the potential pathways linking psoriasis severity and arterial inflammation.
Discussion
In this well-characterized cohort of patients with psoriasis, we demonstrate 6 principal findings: (1) metabolic derangement and subclinical systemic inflammation in psoriasis; (2) psoriasis severity, assessed by PASI score, was associated with aortic vascular inflammation, as measured by aortic TBR, beyond cardiovascular risk factors; (3) psoriasis severity predicted vascular inflammation beyond FRS and highsensitivity C-reactive protein; (4) cytokines associated with innate immune activation were increased in psoriasis blood; (5) neutrophil frequency, activation, chemoattractant cytokines, and protein markers were elevated in psoriasis blood; and (6) S100A8/A9 was related to both skin disease severity and vascular inflammation beyond the FRS.
Several studies demonstrate that psoriasis patients are at increased risk of cardiovascular diseases. [2] [3] [4] [5] [7] [8] [9] 33 Moreover, severe psoriasis is independently associated with atherosclerotic cardiovascular disease. 2, 33 Recent studies further demonstrate that the risk of cardiovascular events, cardiovascular death, and reduced life expectancy because of cardiovascular death are increased in severe psoriasis, particularly younger individuals, and is comparable to that seen in diabetics. 34, 35 Although some of the cardiovascular risk seen in this patient population may be related to the increased rates of obesity, hypertension, diabetes mellitus, hyperlipidemia, metabolic syndrome, and smoking observed in psoriasis patients, the chronic systemic inflammation associated with skin inflammation in psoriasis likely contributes to this risk. 2, 3, 5, 33 FDG is a reliable and reproducible biomarker for atherosclerosis in at-risk populations, allowing for noninvasive measurement of vessel wall inflammation. 36 Vascular uptake of FDG represents cells important in atherosclerosis. 17 FDG uptake in the vasculature associates with cardiovascular disease biomarkers and unstable atherosclerotic plaques, 36, 37 predicts vascular calcifications, 38 detects changes in atherosclerotic plaque inflammation in participants with cardiovascular disease or with high risk of cardiovascular disease, 18 and reduces with treatment for cardiovascular disease risk factors in animal models 32 and humans with lifestyle modification and statin therapy. 17, 18, 21, 22 Furthermore, a recent investigation in HIV patients demonstrated a relationship between arterial inflammation detected by FDG PET/CT and high-risk coronary atherosclerotic plaque, 19 which are predominantly made up of cells present in psoriatic plaques. Similarly, increased FDG vascular uptake is shown in other inflammatory conditions associated with higher cardiovascular disease risk, including rheumatoid arthritis. 20 FDG PET/CT can detect vascular inflammation in the setting of psoriasis, and we observed increased inflammation in severe psoriasis as compared with mild psoriasis and the general population. These data indicate that FDG PET/CT serves as a tool to examine vascular inflammation in patients with psoriasis. The association between severity of skin disease and vascular inflammation found in our study suggests a potentially shared immune-mediated mechanism. Traditionally, this was deemed to be T lymphocyte-mediated, with some contributions from dendritic cells and monocytes in the setting of proinflammatory cytokines. Inflammatory mediators produced by these cells in psoriatic plaques circulate systemically, thereby affecting various tissues, including vascular endothelium, and leading to vascular inflammation and atherosclerotic disease. 24 In support of this model, transcriptome analysis demonstrated that cytokines and chemokines upregulated in psoriasis are also increased in atherosclerosis, Figure 6 . Circulating S100A8/A9 levels are associated with psoriasis severity and vascular inflammation by 18 F-fluorodeoxyglucose positron emission tomography computed tomography (FDG PET/ CT). A, Regression plots for multivariable regression analysis of S100A8/A9 with psoriasis area and severity index (PASI) score for untreated psoriasis patients. B, Regression plots for multivariable regression analysis of S100A8/A9 with vascular inflammation as measured by target-to-background ratio (TBR). CI indicates confidence interval. December 2015 including IL-8, IL-36, and chemokine ligand-2. 26 In our study, we observed elevated psoriasis biomarkers, tumor necrosis factor-α, and IL-6, which also contribute to the development of atherosclerosis, 39 although IL-6 was not significant after correction for multiple testing.
The role of neutrophils in psoriasis is recently gaining interest given the success of anti-IL-17 therapy. 40 In addition to being the earliest cell types present in psoriatic plaques 41 and one of the predominant cellular sources of proinflammatory cytokine IL-17, 29 neutrophils also play an important role in psoriasis comorbidities, such as atherosclerotic diseases. 30, [42] [43] [44] These data suggest that neutrophils may play a role in perpetuating psoriasis and its comorbidities. 29, 31, 45 Interestingly, the cocktail of T-lymphocyte-derived cytokines, IL-17A, tumor necrosis factor-α, and GM-CSF, that effect neutrophil biology were elevated in psoriasis in our study, 31 although IL-17A and GM-CSF were not significant after correction for multiple testing. We also found an increased frequency of circulating neutrophils in psoriasis subjects, concomitant with an activated neutrophil phenotype evident by increased shedding of the Fc receptor CD16 46 and CD62L, the L-selectin responsible for the tethering and rolling of leukocytes to the endothelium. 47 The downregulation of CD16 and CD62L on psoriatic neutrophils suggests an impaired ability to mediate inflammatory damage and a heightened state of activation. This may affect effector functions of neutrophils in vivo and adversely influence the capacity of endothelial cells to support subsequent interactions with circulating leukocytes. Further, neutrophil markers, including serum MPO, S100A8/A9, and NE-1 levels, in our psoriasis cohort were significantly higher than in patients without psoriasis, although MPO weakly met statistical significance after correction for multiple testing. Neutrophil MPO is thought to play a role in initiation, propagation, and acute complications of atherosclerosis, 48 and NE-1 is a serine protease which has been shown to be increased at sites of thrombosis and thus has been implicated in the pathogenesis of acute coronary syndrome. 49 S100A8/A9 (MRP8/14) is a heterodimeric protein complex synthesized by activated neutrophils and abundant in various inflammatory diseases, including psoriasis, where levels are upregulated in lesional skin. 50 Of note, although S100A8/A9 plays an important role in increasing circulating neutrophils and may thereby contribute to cardiovascular disease pathogenesis, 51, 52 it is not a neutrophil-specific marker. In our study, we demonstrated that S100A8/A9 was associated with PASI score. Furthermore, S100A8/A9 was also related strongly to vascular inflammation, suggesting that neutrophil activity may provide important biological links between vascular inflammation and psoriasis. Our observation that the psoriatic atherosclerotic milieu is upregulated in concert with markers of neutrophil activation underscores the concept that atherosclerosis may involve complex neutrophil biology, which future studies should focus on elucidating, especially after intervention.
To our knowledge, this study is the first attempt at systematic characterization of psoriasis severity and aortic vascular inflammation. Our study is limited by the cross-sectional design and inability to prove causality. Ongoing studies of treatment effect (NCT01553058) and outcomes (NCT01778569) aim to elucidate these relationships. We acknowledge that FDG is a surrogate marker for vascular inflammation. However, ongoing studies with directly quantified coronary artery disease using coronary CT angiography concurrently with FDG PET/CT are currently underway (NCT01778569), which will elucidate the accuracy of FDG PET/CT as a marker of coronary artery disease. We also acknowledge that the protein measurements, including cytokines and chemokines, tested in this study, including IL-6, IL-17, and GM-CSF, did not meet statistical significance after Bonferroni correction for multiple testing.
Conclusions
In conclusion, this study provides strong evidence that psoriasis severity is linked with increased vascular inflammation beyond risk factors for vascular disease. Furthermore, psoriasis severity predicted vascular inflammation beyond the FRS, suggesting that psoriasis plaques are biologically active in promoting inflammation at remote sites. Finally, we demonstrate evidence of increased neutrophil activation and neutrophil markers and that S100A8/A9 is related to both skin disease and vascular inflammation, suggesting an important role of neutrophils in psoriasis-associated cardiovascular disease.
